Thromb Haemost 2020; 120(01): 044-054
DOI: 10.1055/s-0039-1698460
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Interpretation and Validation of Maximum Absorbance Data Obtained from Turbidimetry Analysis of Plasma Clots

1   Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa
,
2   Department of Physics, Wake Forest University, Winston-Salem, North Carolina, United States
,
1   Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa
,
1   Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa
› Institutsangaben
Funding This work was supported by the National Research Foundation (grant numbers 120070 and 105700 to M.P.) and the Medical Research Society (Self-Initiated Research Grant to M.P.) of South Africa, by the National Heart, Lung, and Blood Institute of the National Institutes of Health (U.S.A.) under Award Number R15HL148842, and by Wake Forest University Pilot grant DM0741. Opinions expressed and conclusions arrived at are solely the responsibility of the authors and do not necessarily represent the official views of the funders.
Weitere Informationen

Publikationsverlauf

22. Juli 2019

23. August 2019

Publikationsdatum:
21. November 2019 (online)

Abstract

Turbidimetry is used to characterize fibrin clot properties. In purified systems, maximum absorbance (MA) directly relates to fibrin fiber cross-sectional area. However, in plasma samples there are discrepancies in the relationships between MA and fibrinogen concentration, fiber diameter, other clot properties, and cardiovascular disease outcomes, which complicate data interpretation. This study aims to advance understanding of MA of plasma clots through testing how well it relates to fundamental dependence on fibrinogen concentration and fiber diameter as predicted by light scattering theory, other clot properties and lifestyle, and biochemical variables. Plasma samples from 30 apparently healthy individuals with a fibrinogen concentration from 2.4 to 6.4 g/L were included. We performed turbidimetry, permeability, scanning electron microscopy, and rheometry on in vitro formed plasma clots. MA correlated more strongly with fibrinogen concentration (r = 0.65; p < 0.001) than with fiber diameter (r = 0.47; p = 0.01), which combined explained only 46% of the MA variance. Of additional variables measured, only low-density lipoprotein cholesterol correlated with MA (r = 0.46; p = 0.01) and clot lysis (r = 0.62; p < 0.0001) but not with fiber diameter or fibrinogen concentration. MA correlated with clot lysis time (r = 0.59; p = 0.001), storage modulus (r = 0.61; p = 0.001), and loss modulus (r = 0.59; p = 0.001), and negatively with clot permeability (r = –0.60; p = 0.001) also after adjustment for fibrinogen concentration and fiber diameter. Increased MA is indicative of a prothrombotic clot phenotype irrespective of fibrinogen concentration. MA is more indicative of overall clot density than of fiber diameter. Other plasma components can alter internal fiber density without altering fiber diameter and should be considered when interpreting MA of plasma samples.

Authors' Contributions

M.P. and Z.d.L. designed the research; Z.d.L. and C.N. performed the experiments and analyzed the data; M.P., M.G., and Z.d.L. critically evaluated the results and wrote the manuscript. All authors approved the final manuscript and figures.


Supplementary Material

 
  • References

  • 1 Carter AM, Cymbalista CM, Spector TD, Grant PJ. ; EuroCLOT Investigators. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27 (12) 2783-2789
  • 2 Sjøland JA, Sidelmann JJ, Brabrand M. , et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98 (02) 339-345
  • 3 Carr Jr ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11 (01) 46-50
  • 4 Yeromonahos C, Polack B, Caton F. Nanostructure of the fibrin clot. Biophys J 2010; 99 (07) 2018-2027
  • 5 Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63 (01) 111-128
  • 6 Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ. ; Subcommittee on Factor XIII and Fibrinogen, and the Subcommittee on Fibrinolysis. An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (05) 1007-1012
  • 7 Ferry JD, Morrison PR. Preparation and properties of serum and plasma proteins; the conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 1947; 69 (02) 388-400
  • 8 Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25 (1-2): 51-70
  • 9 Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997 (1-2): 96-110
  • 10 Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014; 12 (10) 1687-1696
  • 11 Piechocka IK, Jansen KA, Broedersz CP, Kurniawan NA, MacKintosh FC, Koenderink GH. Multi-scale strain-stiffening of semiflexible bundle networks. Soft Matter 2016; 12 (07) 2145-2156
  • 12 Leonidakis KA, Bhattacharya P, Patterson J. , et al. Fibrin structural and diffusional analysis suggests that fibers are permeable to solute transport. Acta Biomater 2017; 47: 25-39
  • 13 Ferri F, Calegari GR, Molteni M, Cardinali B, Magatti D, Rocco M. Size and density of fibers in fibrin and other filamentous networks from turbidimetry: beyond a revisited Carr–Hermans method, accounting for fractality and porosity. Macromolecules 2015; 48 (15) 5423-5432
  • 14 Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31 (12) e88-e99
  • 15 Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106 (15) 1938-1942
  • 16 Undas A, Podolec P, Zawilska K. , et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 2009; 40 (04) 1499-1501
  • 17 Pera J, Undas A, Topor-Madry R, Jagiella J, Klimkowicz-Mrowiec A, Slowik A. Fibrin clot properties in acute stroke: what differs cerebral hemorrhage from cerebral ischemia?. Stroke 2012; 43 (05) 1412-1414
  • 18 Siudut J, Świat M, Undas A. Altered fibrin clot properties in patients with cerebral venous sinus thrombosis: association with the risk of recurrence. Stroke 2015; 46 (09) 2665-2668
  • 19 Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4 (05) 1029-1036
  • 20 Undas A, Zawilska K, Ciesla-Dul M. , et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
  • 21 Undas A, Zalewski J, Krochin M. , et al. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol 2010; 30 (02) 276-282
  • 22 Undas A, Nowakowski T, Cieśla-Dul M, Sadowski J. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011; 215 (02) 481-486
  • 23 Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006; 4 (05) 973-975
  • 24 Bouman AC, McPherson H, Cheung YW. , et al. Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. Thromb Res 2016; 137: 85-91
  • 25 Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S. ; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158 (01) 1-7
  • 26 Sathiyakumar V, Park J, Golozar A. , et al. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy. Circulation 2018; 137 (01) 10-19
  • 27 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106 (13) 4176-4183
  • 28 Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105 (03) 1102-1105
  • 29 Pieters M, Undas A, Marchi R, De Maat MP, Weisel J, Ariëns RA. ; Factor XIII And Fibrinogen Subcommittee Of The Scientific Standardisation Committee Of The International Society For Thrombosis And Haemostasis. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost 2012; 10 (10) 2179-2181
  • 30 Mosesson MW, DiOrio JP, Siebenlist KR, Wall JS, Hainfeld JF. Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular junction. Blood 1993; 82 (05) 1517-1521
  • 31 Siebenlist KR, Mosesson MW. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem 1994; 269 (45) 28414-28419
  • 32 Blombäck B. Fibrinogen and fibrin--proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83 (01) 1-75
  • 33 Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5 (Suppl. 01) 116-124
  • 34 Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114 (23) 4886-4896
  • 35 Carr Jr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 6 (06) 567-573
  • 36 Collet JP, Woodhead JL, Soria J. , et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 1996; 70 (01) 500-510
  • 37 Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76 (04) 535-540
  • 38 Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117 (18) 4953-4963
  • 39 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125 (04) 357-361
  • 40 Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost 2012; 107 (06) 1180-1182
  • 41 Skrzydlewski Z. Coupling of fibrin with low density lipoproteins. Acta Med Acad Sci Hung 1976; 33 (02) 171-177
  • 42 Kim JA, Kim JE, Song SH, Kim HK. Influence of blood lipids on global coagulation test results. Ann Lab Med 2015; 35 (01) 15-21
  • 43 Bhasin N, Ariëns RA, West RM, Parry DJ, Grant PJ, Scott DJ. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg 2008; 48 (06) 1497-1503
  • 44 Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68 (02) 130-135
  • 45 Puccetti L, Pasqui AL, Pastorelli M. , et al. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects. Int J Clin Pharmacol Res 2001; 21 (3-4): 147-155
  • 46 Kunz F, Pechlaner C, Erhart R, Zwierzina WD, Kemmler G. Increased lipid binding to thrombi in coronary artery disease. Findings in patients without premedication in native (not anticoagulated) test systems. Arterioscler Thromb 1992; 12 (12) 1516-1521
  • 47 Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry 1991; 30 (27) 6671-6677
  • 48 Azizova OA, Roitman EV, Dement'eva II, Nikitina NA, Gagaeva EV, Lopukhin YM. Effects of low-density lipoproteins on blood coagulation and fibrinolytic activity. Bull Exp Biol Med 2000; 129 (06) 541-544
  • 49 Ariëns RA. Novel mechanisms that regulate clot structure/function. Thromb Res 2016; 141 (Suppl. 02) S25-S27
  • 50 Domingues MM, Macrae FL, Duval C. , et al. Thrombin and fibrinogen γ′ impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood 2016; 127 (04) 487-495